Abstract
In a double-blind between-patient clinical trial, 82 patients were admitted to the study and after a preliminary period with placebo administered in single-blindness, they were divided into two groups: 'placebo-responders' and 'placebo non-responders'. Responders were treated with pirprofen capsules (400 mg, b.i.d.) or placebo capsules b.i.d.; non-responders were treated with pirprofen capsules (400 mg, b.i.d.) or naproxen capsules (250 mg, b.i.d.) according to two different randomisation lists, for four menstrual cycles. A complete medical examination, including evaluation of associated symptomatology, menstrual flow entity and global efficacy, was performed after each cycle. In the responders group results were significantly better with pirprofen than with placebo after only the second cycle of treatment (p
| Original language | English |
|---|---|
| Pages (from-to) | 699-705 |
| Number of pages | 7 |
| Journal | Drugs under Experimental and Clinical Research |
| Volume | 13 |
| Issue number | 11 |
| Publication status | Published - 1987 |
Fingerprint
ASJC Scopus subject areas
- Molecular Medicine
- Pharmacology (medical)
- Drug Discovery
- Pharmacology
Cite this
Pirprofen, naproxen and placebo in the treatment of primary dysmenorrhoea. / Marchini, M.; Fedele, L.; Garagiola, U.; Maresca, V.
In: Drugs under Experimental and Clinical Research, Vol. 13, No. 11, 1987, p. 699-705.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Pirprofen, naproxen and placebo in the treatment of primary dysmenorrhoea
AU - Marchini, M.
AU - Fedele, L.
AU - Garagiola, U.
AU - Maresca, V.
PY - 1987
Y1 - 1987
N2 - In a double-blind between-patient clinical trial, 82 patients were admitted to the study and after a preliminary period with placebo administered in single-blindness, they were divided into two groups: 'placebo-responders' and 'placebo non-responders'. Responders were treated with pirprofen capsules (400 mg, b.i.d.) or placebo capsules b.i.d.; non-responders were treated with pirprofen capsules (400 mg, b.i.d.) or naproxen capsules (250 mg, b.i.d.) according to two different randomisation lists, for four menstrual cycles. A complete medical examination, including evaluation of associated symptomatology, menstrual flow entity and global efficacy, was performed after each cycle. In the responders group results were significantly better with pirprofen than with placebo after only the second cycle of treatment (p
AB - In a double-blind between-patient clinical trial, 82 patients were admitted to the study and after a preliminary period with placebo administered in single-blindness, they were divided into two groups: 'placebo-responders' and 'placebo non-responders'. Responders were treated with pirprofen capsules (400 mg, b.i.d.) or placebo capsules b.i.d.; non-responders were treated with pirprofen capsules (400 mg, b.i.d.) or naproxen capsules (250 mg, b.i.d.) according to two different randomisation lists, for four menstrual cycles. A complete medical examination, including evaluation of associated symptomatology, menstrual flow entity and global efficacy, was performed after each cycle. In the responders group results were significantly better with pirprofen than with placebo after only the second cycle of treatment (p
UR - http://www.scopus.com/inward/record.url?scp=0023597221&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0023597221&partnerID=8YFLogxK
M3 - Article
C2 - 3327669
AN - SCOPUS:0023597221
VL - 13
SP - 699
EP - 705
JO - Drugs under Experimental and Clinical Research
JF - Drugs under Experimental and Clinical Research
SN - 0378-6501
IS - 11
ER -